NSCLC

[Science Translational Medicine] Investigators found that antiangiogenic treatment facilitated non–small cell lung cancer tumor infiltration by PD-1+ regulatory T cells, which were more efficiently targeted by the PD-1 antibody than CD8+ T cells.

[Chemistry & Biodiversity] A549 and H1299 non-small lung cancer cell types were used for cytotoxicity using SRB and ATP assays. Fluorescent staining and M30 antigen assay were carried out for cell death evaluation.

[Bioengineered] All hub genes were overexpressed in tumor tissue, and high expression of AURKB, CDC20, TPX2, and KIF2C correlated with the poor prognosis of non-small cell lung cancer patients. In vitro experiments confirmed that CDC20 knockdown inhibited cell proliferation and growth.

[Nature Communications] Scientists showed that the deubiquitinase USP12 was commonly downregulated in the KrasG12D-driven mouse lung tumour and human non-small cell lung cancer owing to the activation of AKT-mTOR signalling.

[Cancer Discovery] The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.

[British Journal of Cancer] Scientists highlight regulatory mechanisms and signaling pathways that cause therapy-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.